Use of Mass Spectrometry to Screen Glycan Early Markers in Hepatocellular Carcinoma.

ABSTRACT: Association between altered glycosylation patterns and poor prognosis in cancer points glycans as potential specific tumor markers. Most proteins are glycosylated and functionally arranged on cell surface and extracellular matrix, mediating interactions and cellular signaling. Thereby, aberrant glycans may be considered a pathological phenotype at least as important as changes in protein expression for cancer and other complex diseases. As most serum glycoproteins have hepatic origin, liver disease phenotypes, such as hepatocellular carcinoma (HCC), may present altered glycan profile and display important modifications. One of the prominent obstacles in HCC is the diagnostic in advanced stages when patients have several liver dysfunctions, limiting treatment options and life expectancy. Th

SUBMITTER: de Oliveira RM 

PROVIDER: S-EPMC5775512 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature